Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 3
2011 3
2012 4
2013 5
2014 3
2015 2
2016 5
2017 6
2018 4
2019 1
2020 4
2021 4
2022 2
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Pathway inhibition: emerging molecular targets for treating glioblastoma.
Wick W, Weller M, Weiler M, Batchelor T, Yung AW, Platten M. Wick W, et al. Neuro Oncol. 2011 Jun;13(6):566-79. doi: 10.1093/neuonc/nor039. Neuro Oncol. 2011. PMID: 21636705 Free PMC article. Review.
Therefore, the identification of novel molecular targets and inhibitory agents has become a focus of research for glioblastoma treatment. ...This review discusses limitations in the existing therapy for glioblastoma and provides an overview of c …
Therefore, the identification of novel molecular targets and inhibitory agents has become a focus of research for glioblast
Emerging therapeutic targets for cerebral edema.
Jha RM, Raikwar SP, Mihaljevic S, Casabella AM, Catapano JS, Rani A, Desai S, Gerzanich V, Simard JM. Jha RM, et al. Expert Opin Ther Targets. 2021 Nov;25(11):917-938. doi: 10.1080/14728222.2021.2010045. Epub 2022 Jan 2. Expert Opin Ther Targets. 2021. PMID: 34844502 Free PMC article. Review.
Current treatment options are limited, reactive, and associated with significant morbidity. Targeted therapies are emerging based on a growing understanding of the molecular underpinnings of cerebral edema. AREAS COVERED: We review the pathophysiology and rel …
Current treatment options are limited, reactive, and associated with significant morbidity. Targeted therapies are emerging ba …
Galectins as Emerging Glyco-Checkpoints and Therapeutic Targets in Glioblastoma.
Videla-Richardson GA, Morris-Hanon O, Torres NI, Esquivel MI, Vera MB, Ripari LB, Croci DO, Sevlever GE, Rabinovich GA. Videla-Richardson GA, et al. Int J Mol Sci. 2021 Dec 28;23(1):316. doi: 10.3390/ijms23010316. Int J Mol Sci. 2021. PMID: 35008740 Free PMC article. Review.
Despite recent advances in diagnosis and treatment, glioblastoma (GBM) represents the most common and aggressive brain tumor in the adult population, urging identification of new rational therapeutic targets. ...Particularly in GBM, galectins control tumor cell tran …
Despite recent advances in diagnosis and treatment, glioblastoma (GBM) represents the most common and aggressive brain tumor in the a …
An Insight into Emerging Phytocompounds for Glioblastoma Multiforme Therapy.
Prakash V, Gabrani R. Prakash V, et al. Cardiovasc Hematol Agents Med Chem. 2023 Nov 10. doi: 10.2174/0118715257262003231031171910. Online ahead of print. Cardiovasc Hematol Agents Med Chem. 2023. PMID: 37957904
Despite intense research in the field of glioblastoma multiforme (GBM) therapeutics, the resistance against approved therapy remains an issue of concern. ...The phytocompounds comprised in these classes are extracted or processed from certain plant sources. They can …
Despite intense research in the field of glioblastoma multiforme (GBM) therapeutics, the resistance against approved therapy r …
Leveraging extrachromosomal DNA to fine-tune trials of targeted therapy for glioblastoma: opportunities and challenges.
Noorani I, Mischel PS, Swanton C. Noorani I, et al. Nat Rev Clin Oncol. 2022 Nov;19(11):733-743. doi: 10.1038/s41571-022-00679-1. Epub 2022 Sep 21. Nat Rev Clin Oncol. 2022. PMID: 36131011 Review.
Glioblastoma evolution is facilitated by intratumour heterogeneity, which poses a major hurdle to effective treatment. ...Notably, targeted therapies inhibiting oncogenic pathways have failed to improve glioblastoma outcomes. ...
Glioblastoma evolution is facilitated by intratumour heterogeneity, which poses a major hurdle to effective treatment. ...Notably,
A Key Pathway to Cancer Resilience: The Role of Autophagy in Glioblastomas.
Jandrey EHF, Bezerra M, Inoue LT, Furnari FB, Camargo AA, Costa ÉT. Jandrey EHF, et al. Front Oncol. 2021 Jun 10;11:652133. doi: 10.3389/fonc.2021.652133. eCollection 2021. Front Oncol. 2021. PMID: 34178638 Free PMC article. Review.
Drug resistance is mostly driven by tumor cell plasticity: a concept associated with reactivating transcriptional programs in response to adverse and dynamic conditions from the tumor microenvironment. Autophagy, or "self-eating", pathway is an emerging target
Drug resistance is mostly driven by tumor cell plasticity: a concept associated with reactivating transcriptional programs in response to ad …
Inhibition of the de novo pyrimidine biosynthesis pathway limits ribosomal RNA transcription causing nucleolar stress in glioblastoma cells.
Lafita-Navarro MC, Venkateswaran N, Kilgore JA, Kanji S, Han J, Barnes S, Williams NS, Buszczak M, Burma S, Conacci-Sorrell M. Lafita-Navarro MC, et al. PLoS Genet. 2020 Nov 17;16(11):e1009117. doi: 10.1371/journal.pgen.1009117. eCollection 2020 Nov. PLoS Genet. 2020. PMID: 33201894 Free PMC article.
Metabolic adaptations leading to increased synthesis of nucleotides by de novo biosynthesis pathways are emerging as key alterations driving glioblastoma growth. ...Our study demonstrates that glioblastoma cells heavily rely on the de novo pyrimidine b …
Metabolic adaptations leading to increased synthesis of nucleotides by de novo biosynthesis pathways are emerging as key alter …
Epidermal growth factor receptor targeting and challenges in glioblastoma.
Thorne AH, Zanca C, Furnari F. Thorne AH, et al. Neuro Oncol. 2016 Jul;18(7):914-8. doi: 10.1093/neuonc/nov319. Epub 2016 Jan 10. Neuro Oncol. 2016. PMID: 26755074 Free PMC article. Review.
Greater characterization of glioblastoma at the molecular level has improved its initial pathophysiological staging and classification. ...In this review, we provide a brief overview of EGFR and its mutated form, EGFR variant III, describing the downstream cellular …
Greater characterization of glioblastoma at the molecular level has improved its initial pathophysiological staging and classi …
The dopamine receptor D1 inhibitor, SKF83566, suppresses GBM stemness and invasion through the DRD1-c-Myc-UHRF1 interactions.
Xue Z, Zhang Y, Zhao R, Liu X, Grützmann K, Klink B, Zhang X, Wang S, Zhao W, Sun Y, Han M, Wang X, Hu Y, Liu X, Yang N, Qiu C, Li W, Huang B, Li X, Bjerkvig R, Wang J, Zhou W. Xue Z, et al. J Exp Clin Cancer Res. 2024 Jan 22;43(1):25. doi: 10.1186/s13046-024-02947-7. J Exp Clin Cancer Res. 2024. PMID: 38246990 Free PMC article.
Knockdown and overexpression experiments were performed to find molecular pathways responsible for the therapeutic effects of SKF83566. ...Using CMap analysis, SKF83566 was identified as a selective inhibitor targeting both DRD1 and DRD5. In vitro studies dem …
Knockdown and overexpression experiments were performed to find molecular pathways responsible for the therapeutic effects of …
Current and future therapeutic strategies for high-grade gliomas leveraging the interplay between epigenetic regulators and kinase signaling networks.
Stitzlein LM, Adams JT, Stitzlein EN, Dudley RW, Chandra J. Stitzlein LM, et al. J Exp Clin Cancer Res. 2024 Jan 5;43(1):12. doi: 10.1186/s13046-023-02923-7. J Exp Clin Cancer Res. 2024. PMID: 38183103 Free PMC article. Review.
Targeted therapies, including small molecule inhibitors directed against aberrant kinase signaling and chromatin regulators, are emerging treatment options for high-grade gliomas (HGG). ...Several studies have demonstrated improved efficacy from the dual inhibiti
Targeted therapies, including small molecule inhibitors directed against aberrant kinase signaling and chromatin regulators, are e
49 results